DiaSorin: Difference between revisions
Created a new paragraph from the History section, about the acquisitions. |
Added clarifications and sources to CLIA and ELISA technologies |
||
| Line 53: | Line 53: | ||
DiaSorin develops, manufactures and markets tests for the diagnosis of infectious diseases or hormonal disorders. The immunodiagnostic and molecular tests are aimed at both private and hospital analysis laboratories worldwide. |
DiaSorin develops, manufactures and markets tests for the diagnosis of infectious diseases or hormonal disorders. The immunodiagnostic and molecular tests are aimed at both private and hospital analysis laboratories worldwide. |
||
In immunodiagnostics, DiaSorin offers the market proprietary-based platforms on the [[CLIA]]<ref>{{Cite journal|last=Cinquanta|first=Luigi|last2=Fontana|first2=Desré Ethel|last3=Bizzaro|first3=Nicola|date=2017-06-24|title=Chemiluminescent immunoassay technology: what does it change in autoantibody detection?|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483212/|journal=Auto-Immunity Highlights|volume=8|issue=1|doi=10.1007/s13317-017-0097-2|issn=2038-0305|pmc=5483212|pmid=28647912}}</ref> and [[ELISA]]<ref>{{Cite journal|last=Engvall|first=Eva|last2=Perlmann|first2=Peter|date=1972-07-01|title=Enzyme-Linked Immunosorbent Assay, Elisa: III. Quantitation of Specific Antibodies by Enzyme-Labeled Anti-Immunoglobulin in Antigen-Coated Tubes|url=https://www.jimmunol.org/content/109/1/129|journal=The Journal of Immunology|language=en|volume=109|issue=1|pages=129–135|issn=0022-1767|pmid=4113792}}</ref> technologies. |
|||
In immunodiagnostics, DiaSorin offers the market proprietary-based platforms on the [[CLIA]]{{clarify|What is CLIA?|date=September 2020}} and [[ELISA]]{{clarify|What is ELISA?|date=September 2020}} technologies. |
|||
In molecular diagnostics, DiaSorin offers proprietary platforms that cover the three phases of the testing process: extraction, amplification and detection.<ref>{{Cite web|url=https://www.diasorin.com/sites/default/files/docs/diasorin_s.p.a.-annual_financial_report_2017_0.pdf|title=DiaSorin - Annual Financial Report 2017|last=|first=|date=|website=|archive-url=|archive-date=|access-date=}}</ref> |
In molecular diagnostics, DiaSorin offers proprietary platforms that cover the three phases of the testing process: extraction, amplification and detection.<ref>{{Cite web|url=https://www.diasorin.com/sites/default/files/docs/diasorin_s.p.a.-annual_financial_report_2017_0.pdf|title=DiaSorin - Annual Financial Report 2017|last=|first=|date=|website=|archive-url=|archive-date=|access-date=}}</ref> |
||
Revision as of 07:46, 9 October 2020
.svg){kind=logo} | |
| Company type | Società per azioni |
|---|---|
| BIT: DIA | |
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | , Italy |
Key people | Gustavo Denegri (Chairman) Carlo Rosa (CEO) |
| Products | In vitro diagnostics instruments and services |
| Revenue |  €706,3 million[1] (2019) |
Number of employees | 2,000(2019)[1] |
| Website | diasoringroup |
DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. The group was founded in 2000 and is headquartered in Saluggia, Italy. Its production is at several plants located in Europe and the United States: Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), Dartford (UK). The company is a constituent of the FTSE Italia Mid Cap index.
The Group is active in the development, production and marketing of diagnostic tests used by the medical community to assess a patient’s values, understand their state of health or monitor the progression of a disease.
DiaSorin offers diagnostic assays employing two of the most common technologies in in vitro diagnostics: immunodiagnostics and molecular diagnostics. Both technologies are based on automated technological platforms developed by DiaSorin in collaboration with partner companies on specifications provided by DiaSorin.
DiaSorin’s “core business” is, however, the design and development of diagnostic test kits (reagents and other materials) that run on such platforms.
DiaSorin also focuses on the development of research and laboratory kits in the field of molecular diagnostics, particularly specializing in the infectious diseases sector with different matrices including blood, cerebrospinal fluid, cutaneous and mucus swabs.[2][3]
Activities
DiaSorin focuses its efforts on several fields of immunodiagnostics: infectious diseases, bone and mineral, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmunity and brain and cardiac markers.
The company is also active in molecular diagnostics for infectious diseases and for the detection of some forms of leukemia.[4]
DiaSorin develops, manufactures and markets tests for the diagnosis of infectious diseases or hormonal disorders. The immunodiagnostic and molecular tests are aimed at both private and hospital analysis laboratories worldwide.
In immunodiagnostics, DiaSorin offers the market proprietary-based platforms on the CLIA[5] and ELISA[6] technologies.
In molecular diagnostics, DiaSorin offers proprietary platforms that cover the three phases of the testing process: extraction, amplification and detection.[7]
History
The origins of the company date back to 1968, when near Vercelli on an initiative of Fiat and Montecatini, the "Sorin Biomedica" was founded by the "Società Ricerche Impianti Nucleari - Sorin".[8] In 1997 the company acquired control of American Incstar, and part of its operations were later sold to American Standard.[8] DiaSorin was founded in 2000, through a management buyout operation led by Carlo Rosa and Gustavo Denegri.[9]
The etymology of the name contains the acronym of Sorin, "Nuclear plant research company", the company established in the 1960s, and "Dia" which stands for Diagnostics. In 1997 Sorin decided to build upon the activities relating to in vitro diagnostics into a company that took on the name of DiaSorin.[10]
Acquisitions
In 2002 DiaSorin acquired BYC Sangtec and the rights to the Liaison platform. The commercial expansion led to the opening of new branches in Mexico, Israel, and China. The Liaison portfolio was enriched with products for new and clinical specialty areas. In the same year, tests previously developed with ELISA technology were converted ton the most recent and automated CLIA.[8]
On July 19, 2007 the DiaSorin title debuted at Borsa Italiana Stock Exchange.[11]
In 2014 the company obtained the approval of hepatitis and retrovirus tests in China; in the same year, DiaSorin launched new tests to detect leukemias. DiaSorin Group signed an agreement in 2015 with Beckman Coulter for the commercialization in China of DiaSorin hepatitis and HIV tests.[12]
In 2016, DiaSorin and Beckman Coulter signed an additional partnership, with the aim to provide customers in the U.S. the same hepatitis and HIV tests. The two companies are working together to submit the products to the Food and Drug administration (FDA) for approval and commercialization in the U.S.[13] In this year, the group acquired of Focus Diagnostics’ business unit, enabling it to expand its activities in molecular diagnostics.[14][15]
In 2017, a partnership with Qiagen offered an automated solution for detection of tuberculosis with QuantiFERON-TB Gold Plus available on the Liaison analyzers. That was also the year of the Siemens Healthineers ELISA business acquisition.[16]
In October 2018 the Saluggia branch began a partnership with Meridian for the distribution of a Helicobacter pylori detection test in the United States and United Kingdom. The companies have put in place a framework under which they may work together on the development of new tests and products.[17]
In 2019 the commercial launch of Liaison XS approval of latent tuberculosis test in the United States.[18]
In February and March 2020, from the novel coronavirus pandemia, DiaSorin has devised and developed a molecular diagnostic test intended to detect all the currently known variants of the COVID-19. The test enables sample-to-answer results within less than 60 minutes compared to the 5–7 hours currently necessary to report patient results.[19]
On 7 April 2020, DiaSorin announced the development of a new IgG CLIA test to identify antibodies against SARS-CoV-2 antibody test, that allows to detect antibodies directed against the virus in patients’ serum samples, identifying subjects who have developed an immune response to the virus, offering a tool for epidemiologic assessment of populations.[20]
On 25 April 2020, DiaSorin received Emergency Use Authorization from the U.S. Food and Drug Administration for a new serologic test for COVID-19.[21]
| Shareholder (2019[22]) | Share % |
|---|---|
| Finde SS | 44,97% |
| Rosa Carlo | 8,36% |
| Even Chen Menachem | 4,20% |
| T. Rowe Price Associates, Inc. | 3,03% |
| Market | 39,43% |
Financial data
DiaSorin has been listed on the Italian Stock Exchange since 2007 and is in the FTSE Italy Mid Cap Index.
| (in million Euros)[4] | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales and service revenues | 206,3 | 244,6 | 304,1 | 404,5 | 440 | 433,7 | 434,8 | 443,7 | 449,1 | 569,3 | 637,4 | 669,2 | 706,3 |
| Cost of sales | (73,8) | (84) | (90,4) | (119,8) | (126,1) | (136,4) | (135,1) | (145) | (157,2) | (180,1) | (205,5) | (214,4) | (217,6) |
| Gross profit | 132,5 | 160,6 | 213,6 | 284,7 | 313,8 | 297,3 | 299,6 | 298,7 | 341,8 | 389,1 | 431,9 | 455,8 | 488,7 |
| EBIT | 47,5 | 70,7 | 106,4 | 145,5 | 163,3 | 140,2 | 134,6 | 129,8 | 152 | 172,6 | 184,4 | 204,5 | 217,9 |
| Profit before taxes | 44,1 | 59,8 | 103,7 | 144,9 | 158,2 | 137,4 | 129,3 | 128,1 | 150,1 | 168,1 | 178,7 | 204,4 | 216,3 |
| Net result | 26,3 | 37,4 | 70 | 90,4 | 99,6 | 87,6 | 83,1 | 84 | 100,5 | 112,6 | 139,8 | 158,1 | 175,7 |
| EBITDA | 61,5 | 85,6 | 123,6 | 167,1 | 190 | 169,5 | 163 | 160,2 | 184,9 | 217,3 | 237,9 | 255,4 | 276,8 |
Management
| Role | Name |
|---|---|
| Chairman | Gustavo Denegri |
| Chief Executive Officer | Carlo Rosa |
| President | John Walter |
| Senior Corporate VP e Chief Financial Officer | Piergiorgio Pedron |
| Chief Commercial Officer | Chen Even |
| Senior Corporate VP Human Resources | Stefano Ronchi |
Notes
- ^ a b Cite error: The named reference
fy2019was invoked but never defined (see the help page). - ^ "Diasorin Annual Financial Statements at 12.31.2019" (PDF).
{{cite web}}: CS1 maint: url-status (link) - ^ "Company Profile" (PDF).
{{cite web}}: CS1 maint: url-status (link) - ^ a b "Annual Financial Report at December 31, 2017". Retrieved 30 January 2019.
- ^ Cinquanta, Luigi; Fontana, Desré Ethel; Bizzaro, Nicola (2017-06-24). "Chemiluminescent immunoassay technology: what does it change in autoantibody detection?". Auto-Immunity Highlights. 8 (1). doi:10.1007/s13317-017-0097-2. ISSN 2038-0305. PMC 5483212. PMID 28647912.
- ^ Engvall, Eva; Perlmann, Peter (1972-07-01). "Enzyme-Linked Immunosorbent Assay, Elisa: III. Quantitation of Specific Antibodies by Enzyme-Labeled Anti-Immunoglobulin in Antigen-Coated Tubes". The Journal of Immunology. 109 (1): 129–135. ISSN 0022-1767. PMID 4113792.
- ^ "DiaSorin - Annual Financial Report 2017" (PDF).
- ^ a b c "DiaSorin - Our History".
- ^ "DiaSorin: "Via da Dublino grazie al patent box. Ma ora maggiori certezze"". 16 April 2018. Retrieved 17 April 2018.
- ^ "Our history". DiaSorin. 2018-09-20. Retrieved 2020-10-09.
- ^ "Borsa Italiana - DiaSorin".
- ^ "DiaSorin and Beckman Coulter Form Strategic Partnership to Bring the Liaison XL Hepatitis and HIV Products to the U.S. Market".
- ^ "Diasorin and Beckman Coulter form strategic partnership to bring the liaison xl hepatitis and HIV products to the U.S. market" (PDF).
{{cite web}}: CS1 maint: url-status (link) - ^ "DiaSorin to Acquire Quest's Focus Diagnostics for $300M". GEN.
- ^ "DiaSorin Completes Acquistion [sic] of the Focus Diagnostics' Molecular and Immunoassay Product Business from Quest Diagnostics".
- ^ "DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS".
- ^ "DiaSorin and Meridian Enter Into a Strategic Collaboration to Sell Helicobacter Pylori Stool Antigen Test in the United States and in the United Kingdom".
- ^ "Qiagen, DiaSorin secure US approval for QFT-Plus Test". Verdict Medical Devices. 2019-11-28. Retrieved 2020-04-16.
- ^ "Shares in Diasorin surge ahead of launch of diagnostic test for coronavirus". CNBC. 2020-03-10. Retrieved 2020-04-16.
- ^ "Liaison SARS-CoV-2 IgG". DiaSorin. Retrieved 2020-04-16.
- ^ "Italy's DiaSorin gets U.S. FDA approval for COVID-19 antibody test". Reuters. 2020-04-25. Retrieved 2020-04-28.
- ^ a b "Diasorin official website, Total shareholders' basis". Retrieved 15 April 2020.
- ^ "Diasorin official website". Retrieved 12 July 2019.
- ^ "About us". Retrieved 24 November 2013.